<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04199000</url>
  </required_header>
  <id_info>
    <org_study_id>19-005187</org_study_id>
    <secondary_id>U54NS115198-01</secondary_id>
    <nct_id>NCT04199000</nct_id>
  </id_info>
  <brief_title>Clinical and Basic Investigations Into Congenital Disorders of Glycosylation</brief_title>
  <official_title>Clinical and Basic Investigations Into Congenital Disorders of Glycosylation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to study the natural history of congenital disorders of
      glycosylation and its causes and treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are conducting a natural history study of patients with congenital
      disorders of glycosylation (CDG). The study will look into the progression of the disease
      amongst the participants and also look at the clinical symptoms and how they vary amongst
      different diseased population groups. The participants will be asked to fill out
      questionnaires either on their own or with a provider that will grade the severity of disease
      and document symptoms and diet. Participants will have an opportunity to submit blood, urine,
      and stool samples that will be tested for biomarkers for CDG.

      Participants will also complete dietary food records, physical exams, CDG scores, and the
      PROMIS questionnaires to assess disease progression and severity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Indicators of Disease Severity and Progression - organ system involvement</measure>
    <time_frame>Length of study, up to 5 years</time_frame>
    <description>Establish the prevalence and severity of specific morbid indicators of disease severity through use of the Nijmegen Progression CDG rating scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Indicators of Disease Severity and Progression - degree of cognitive disability</measure>
    <time_frame>Length of study, up to 5 years</time_frame>
    <description>Establish the prevalence and severity of specific morbid indicators of disease severity through use of the Nijmegen Progression CDG rating scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Indicators of Disease Severity and Progression - case-fatality</measure>
    <time_frame>Length of study, up to 5 years</time_frame>
    <description>Establish the prevalence and severity of specific morbid indicators of disease severity through use of the Nijmegen Progression CDG rating scale.</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Congenital Disorders of Glycosylation</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool, urine, and blood can be retained for biomarker testing. DNA may be a part of this
      testing in the future.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients included in the study must have genetic confirmation of a primary congenital
        disorder of glycosylation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with congenital disorders of glycosylation based on genetic
             confirmatory testing

        Exclusion Criteria:

          -  Patients without congenital disorders of glycosylation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Morava-Kozicz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eva Morava-Kozicz, PhD, MD</last_name>
    <phone>507-266-2967</phone>
    <email>morava-kozicz.eva@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kaitlin Schwartz, B.S.</last_name>
    <phone>507-293-9114</phone>
    <email>schwartz.kaitlin@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Morava-Kozicz, MD, PhD</last_name>
      <phone>507-266-2967</phone>
      <email>morava-kozicz.eva@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kailtin Schwartz, B.S.</last_name>
      <phone>507-293-9114</phone>
      <email>Schwartz.kaitlin@mayo.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 8, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>December 13, 2019</last_update_submitted>
  <last_update_submitted_qc>December 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Eva Morava-Kozicz</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Disorders of Glycosylation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data and samples may be shared with other investigators at the discretion of the PI. Only participants who have consented to sharing data/samples will be included in this portion.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Length of study and beyond</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT04199000/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

